Gliomas Harboring IDH1 and/or IDH2 MutationsGlioma Glioblastoma MultiformeGlioma of BrainstemGlioma, Diffuse Midline, H3K27M-mutantGlioma : Oligodendroglioma or AstrocytomaGliomas
Study summary
A vision-language model using preoperative MRI and clinical variables has been developed to simultaneously predict three key molecular markers in midline gliomas: H3K27M, IDH, and 1p/19q. This prospective multicenter study will validate the model's accuracy in preoperative molecular subtyping and its value in prognostic assessment and clinical decision-making across multiple neurosurgical centers.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients with diffuse gliomas were pathologically and molecularly diagnosed.
* The clinical case data of all patients were complete.
* Patients underwent preoperative MRI examination.
Exclusion Criteria:
* The tumor is not located in the intracranial midline.
* Cases in which MRI were incomplete or with significant noise and artifacts.
Primary outcome measure(s)
Diagnostic accuracy for midline glioma molecular subtypes — Perioperative Model predictions compared with postoperative histopathology and molecular testing (gold standard). Performance metrics include AUC, F1 score, sensitivity, specificity, and accuracy.
Trial sites (1)
Facility
City
Region
Status
Xiangya Hospital of Central South University
Changsha
Hunan
Recruiting
More Xiangya Hospital of Central South University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.